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Abstract 
BACKGROUND: This is an out-of-pocket costs analysis of ifosfamide, epirubicin, and etoposide (IEV) and etoposide, 
solu-medrol-methylprednisolone, high-dose ara-C-cytarabine, and platinol-cisplatin (ESHAP) drug regimens in 
treatment of lymphoma in Iran. 
METHODS: This cross-sectional study was conducted in Shiraz City. Data were collected using a data-collection 
form. The social perspective was used to collect cost data. Three types of costs were measured, medical direct 
costs, non-medical direct costs, and indirect costs. 
RESULTS: 65 patients were treated with these two methods; 27 patients were treated with IEV and 38 with ESHAP. 
Moreover, the mean direct cost in IEV and ESHAP regimens in 2014 were 1191.10 ± 610.74 and 1819.57 ± 789.73 
United States dollars (USD), respectively. The difference was statistically significant (P < 0.001). 
CONCLUSION: In this study, costs in the IEV regimen were significantly lower than the ESHAP regimen. This was 
particularly caused by an earlier discharge of patients under IEV regimen; since these patients experienced a trend 
toward less neutropenia and, hence, had a trend toward fewer hospitalization days, the related cost was 3451.76 
USD with savings of 6479.61 USD compared with the ESHAP regimen. Overall, most of patient’s income was spent 
on out-of-pocket costs for all expenditures incurred because of lymphoma. 
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Introduction1 
The number of patients with cancer will 
increase to 24 million in the world by 2035.1 In 
2018, in the United States, there will be an 
estimated 1,050 deaths from Hodgkin 
lymphoma (HL), and 19,910 deaths from non-
Hodgkin lymphoma (NHL). From 2006 to 
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2015, death rates decreased by about 3% per 
year for Hodgkin lymphoma, and 2% per year 
for non-Hodgkin lymphoma.2 
The National Institutes of Health (NIH) 
estimates that the overall costs of cancer contains 
medical direct costs, non-medical direct costs, 
and indirect costs; in 2009, in the United States, 
the costs were totally 216,000,000,000 United 
States dollars (USD), 86,000,000,000 USD caused 
by direct costs, and 130,000,000,000 USD by 
indirect costs.3 It determined that the associated 
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direct costs of cancer care would increase by 
27%, assuming stable incidence, survival, and 
costs; if cost of care increased each year by 2%, in 
the first year after diagnosis and in the last year 
of life, the predicted 2020 cost would increase up 
to 39% from 2010.4 
After primary treatment for Hodgkin and 
non-Hodgkin lymphomas, 10 to 20 percent of 
the patients with early-stage disease, and 35 to 
40 percent of patients with advanced stage at 
diagnosis will suffer a relapse.5,6 Patients who 
are refractory to the first-line therapy or 
relapse at a later stages, need more care.7 
Roughly, 50 to 60 percent of patients who relapse 
may be successfully treated with high-dose 
chemotherapy and stem-cell transplantation.7,8 
Patients with lymphoma are usually treated with 
chemotherapy; radiation, alone or in 
composition with chemotherapy, is used less 
usually.9 Typically, chemotherapy for lymphoma 
is a therapeutic protocol or pharmaceutical 
regimen that includes several drugs. Etoposide, 
solu-medrol-methylprednisolone, high-dose ara-
C-cytarabine, and platinol-cisplatin (ESHAP) is 
a drug regimen,7 which is effective in treating 
refractory or relapsed lymphoma.10 In 
addition, ifosfamide, epirubicin, and etoposide 
(IEV) is a combination of ifosfamide, 
epirubicin, and etoposide.11 
These drug regimens have different effects 
on costs. Because of the various medical costs 
in cancer treatment, and maybe the impact on 
total treatment costs, and also the limited 
information about the costs, we performed a 
study to analysis the costs of IEV versus 
ESHAP, which are commonly used treatments 
for treating these patients in Iran. 
Materials and Methods 
This cross-sectional study was conducted as a 
double-blind study on 65 patients suffering 
from relapsed/refractory lymphoma, in Amir 
Oncology Hospital in Shiraz City, Iran. 
Patients were selected from April 2013 to April 
2014, using goal-oriented sampling. The 
geographic area of study was the urban and 
rural areas of Fars Province. 
We used telephone interviews for 
measuring the costs for household members 
resulted from lymphoma. The data collection 
form was completed during the interview after 
6 months of follow-up at the last (6th) session of 
chemotherapy for each patient. Information on 
type of treatment regimens and drug effects 
was obtained through review of medical 
records. All participants provided signed 
informed consent. All the ethics review 
committees of participating hospital approved 
the study. 
All node-positive patients younger than  
75 years were included. Patients with severe 
renal failures, hepatic impairments, Karnofsky 
Performance Scale Index of less than 70, and 
age older than 75 years, and all the cases of 
metastasis and node negative were excluded.  
The social perspective was used to collect 
cost data for a period of 6 months. Moreover, 
the data collection form was used to collect 
demographic data and costs. We defined out-
of-pocket costs as all costs amounts paid 
directly by the patients due to 
relapsed/refractory lymphoma cancer 
treatment. For patients, out-of-pocket costs 
included costs associated with medical direct 
cost (medication, hospitalization, sonography, 
radiology, magnetic resonance imaging (MRI), 
surgical costs, laboratory tests, computed 
tomography (CT) scan, and follow-up visits), 
non-medical direct costs (travel costs, lodging, 
phone, auxiliary equipment, and special diet 
during chemotherapy), and indirect costs 
(costs of lost production due to absence from 
work) calculated using the Human Capital 
Approach. Out-of-pocket costs were calculated 
by summing these items. We also questioned 
patients about their perceptions of the family’s 
financial situation in the past 6 months, using 
questions administered at the 1-month 
interviews. These questions were adapted 
from published studies and questionnaires.12 
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Specifically, we asked about the patient’s 
satisfaction with their family’s financial 
situation, and their worry about and 
perception of their family’s financial situation 
compared with that of others of the same age. 
For these analyses, patients not working at 
diagnosis were assigned 0 USD in terms of the 
indirect costs. The total of these items were 
treatment costs for each patient, calculated by 
the Iranian Rial (IRR) to USD exchange rate in 
year 2014. 
In order to estimate transmission costs for 
those who travelled with their personal car, we 
used the dimension between the patient’s 
domicile and the treatment hospital. We asked 
the cost of petrol from patients or patients 
accompany. The resulting amount was 
multiplied by two to account for the return 
trip, and then multiplied by the number of 
treatments received. We used the paid amount 
for those travelling by taxi, bus, rail, and air. 
None of the respondents reported having paid 
for parking. For those living away from home, 
we calculated lodging costs by using the cost 
for lodging reported by the respondent, and 0 
USD for respondents who stayed in family or 
friends’ home. The phone costs, auxiliary 
equipment, and special diet were estimated 
using the paid amount by the patients 
multiplied by the number of those. In addition, 
we estimated extra out-of-pocket costs 
incurred because of patients with 
relapsed/refractory lymphoma for indoor and 
outdoor household help, and child care. 
We used descriptive statistical to analyze 
the data via SPSS software (version 16.0, SPSS 
Inc., Chicago, IL, USA). Moreover, the Mann-
Whitney test was used to assess the significant 
differences in costs between the two regimens. 
Besides, 95% of confidence intervals (CIs) were 
computed using non-parametric bootstrapping 
method for costs. 
Results 
According to table 1, in IEV and ESHAP 
regimens, the highest and lowest mean costs 
were medical direct costs (1191.10 ± 610.74 
USD in IEV and 1819.57 ± 789.73 USD in 
ESHAP) and non-medical direct costs  
(237.06 ± 207.42 USD in IEV and 208.39 ± 179.7 
USD in ESHAP), respectively. Moreover, the 
mean medical direct costs was statistically 
lower in IEV regimen than ESHAP regimen  
(P < 0.001). But, for the mean of non-medical 
direct costs and indirect costs and total costs, the 
differences were not statistically significant. 
As seen in table 2, the total cost of 
chemotherapy drugs in the IEV regimen was 
13201.45 USD (488.94 ± 338.57 USD) that was 
highest medical direct costs. Moreover, in the 
ESHAP regimen, this item was 32943.08 USD 
(866.92 ± 354.91 USD). In both regimens, travel 
costs and indirect costs were highest type of 
treatment costs, in IEV regimen, 4037.14 
(149.52 ± 142.95) and 16152.60 (562.2 ± 584.25) 
USD, and in ESHAP regimen, 3980.62  
(104.75 ± 98.56) and 17,359.7 (351.65 ± 666.09) 
USD, respectively. 
 
Table 1. The treatment costs of patients with lymphoma based on the type of costs 
Mean costs  
Type of treatment protocol 
P 
IEV ESHAP 
Medical direct costs 1191.10 ± 610.74 1819.57± 789.73 < 0.001 
Non-medical direct costs 237.06 ± 207.42 208.39 ± 179.7 0.545 
Indirect costs 598.24 ± 584.25 456.83 ± 666.09 0.249 
Total 2026.42 ± 916.91 2484.79 ±1060.27 0.123 
The amounts are in United States dollar (USD). 
IEV: Ifosfamide, epirubicin, and etoposide; ESHAP: Etoposide, solu-medrol-methylprednisolone, high-dose ara-C-
cytarabine, and platinol-cisplatin  
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Table 2. The cost components of Ifosfamide, epirubicin, and etoposide (IEV) and Etoposide, solu-
medrol-methylprednisolone, high-dose ara-C-cytarabine, and platinol-cisplatin (ESHAP) regimens in 
lymphoma as included in the analysis 
Strategy Costs components Costs (USD) The proportion to total costs (%) 
ESHAP Medical direct costs 69,143.72 73.0 
Chemotherapy drugs 32,943.08 35.0 
Hospitalization 9,931.37 11.0 
Sonography 775.13 1.0 
Radiology 2,751.31 3.0 
MRI 621.72 1.0 
Surgical 4,299.56 5.0 
Laboratory tests 8,800.97 9.0 
CT scan 2,955.19 3.0 
Visits 998.79 1.0 
Other 5,066.61 5.0 
Non-medical direct costs 7,918.85 8.0 
Traveling 3,980.62 4.0 
Lodging 2,111.43 2.0 
Phone 890.19 1.0 
Auxiliary equipment 68.63 < 0.1 
Special diet 867.99 1.0 
Indirect costs 17,359.71 18.0 
Time spent by the patient 13,362.94 14.0 
Time spent by the patient’s accompany 3,996.77 4.0 
Total 94,422.29  
IEV Medical direct costs 32,159.87 59.0 
Chemotherapy drugs 13,201.45 24.0 
Hospitalization 3,451.76 6.0 
Sonography 557.13 1.0 
Radiology 1,441.26 3.0 
MRI 282.60 1.0 
Surgical 4,339.93 8.0 
Laboratory tests 3,863.54 7.0 
CT scan 1,929.75 4.0 
Visits 609.61 1.0 
Other 2,482.84 5.0 
Non-medical direct costs 6,400.89 11.0 
Traveling 4,037.14 7.0 
Lodging 1,320.15 2.0 
Phone 680.26 1.0 
Auxiliary equipment 129.19 0.2 
Special diet 234.15 0.4 
Indirect costs 16,152.60 30.0 
Time spent by the patient 15,179.65 28.0 
Time spent by the patient’s accompany 972.95 2.0 
Total 54,713.36  
IEV: Ifosfamide, epirubicin, and etoposide; ESHAP: Etoposide, solu-medrol-methylprednisolone, high-dose ara-C-cytarabine, and 
platinol-cisplatin; USD: United States dollar; MRI: Magnetic resonance imaging; CT: Computed tomography 
 
Discussion 
This was the first cost-analysis in patients with 
lymphoma in Iran. Given that, cancer is one of 
the major causes of death in Iran,13 and 
lymphoma is among the ten most common 
cancers,14 also, IEV and ESHAP drugs regimens 
are common drugs in the treatment of 
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lymphoma, we believe that evaluating the costs 
of these drugs regimens is very necessary. 
Our results in this study indicated that the 
mean direct cost in ESHAP regimen  
(1191.1 ± 610.74 USD) was significantly more 
than IEV regimen (1819.57 ± 789.73 USD). In 
addition, the total cost of chemotherapy in 
ESHAP regimen was 32943.08 (866.92 ± 354.91) 
USD; it was 47.7% of medical direct costs. 
While in IEV regimen, the total cost of 
chemotherapy was 13201.45 (488.94 ± 338.57) 
USD, which was 41.04% of medical direct 
costs. These results could be due to high costs 
of chemotherapy in the ESHAP. Besides, more 
hospitalization would be created more 
paraclinical costs. Regarding the cost analysis, 
absolute comparisons to earlier studies cannot 
be made due to the different methodologies 
and great difference in costs between 
countries. Beard et al.,9 Gruschkus et al.,15 
Kuderer et al.,16 Lee et al.,17 Norum et al.,18 Ray 
et al.19 and Sweetenham et al.,20 concluded that 
the main cost drivers were medical direct 
costs, particularly chemotherapy. Moreover, 
earlier discharge of patients with lymphoma 
would reduce the hospitalization and 
consequently the medical direct costs. 
However, the difference in the mean of non-
medical direct costs and indirect costs in two 
regimens was not significant. The occupation 
and the absence from work determine the 
amount of indirect costs. These items do not 
follow the specific trend in the two groups. So, 
we can say more length of stay reduced 
income further by the more absence from 
work. Some of patients experienced more 
costs, including patients with higher travel 
costs, because of several stages of treatment 
and long courses. Overall, most of patient’s 
income was spent on out-of-pocket costs for all 
expenditures incurred because of lymphoma. 
In the meantime, the ESHAP regimen was 
more expensive compared to the IEV regimen. 
So, insurance coverage should be considered in 
these patients to reduce the out of pocket. 
Some limitations of our study must be 
discussed in evaluating the results. The small 
number of participants and short follow-up 
period can restrict the generalization of the 
findings to other setting. Assessment of a 
longer follow-up period is unlikely to alter our 
main findings, since there is no evidence to 
indicate that follow-up costs after discharge 
would reverse the results. Although our 
sample size was relatively small, it is the 
largest sample of patients with Hodgkin and 
non-Hodgkin lymphoma considered up until 
now in an out-of-pocket costs analysis.  
Due to the difference in costs, 
generalizability to other hospitals may be 
limited. Nevertheless, therapeutic methods is 
similar between this hospital and others. 
Although, we cannot generalize these findings 
to other countries due to socialized medicine, 
worker’s wages and drugs costs are dissimilar.  
Particularly, chemotherapy costs are the 
highest costs in both regimens; but these are 
not covered by insurance, and patients pay 
these costs directly. 
Conclusion 
Since patients with IEV regimen experienced a 
trend toward less neutropenia and, hence, had 
a trend toward fewer hospitalization days, the 
related cost was 3451.76 USD with savings of 
6479.61 USD compared with the ESHAP 
regimen. Overall, most of patient’s income was 
spent on out-of-pocket costs for all 
expenditures incurred because of lymphoma. 
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